FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/04/2022
Voltar para busca
Dado oficial do USPTO
VALPHARMA GROUP
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
10/04/2022
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5
Data de depósito
03/03/2020
Data de registro
05/10/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/10/2021
Última transação
05/10/2021
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
SM
Examinador
PODESTA, GIDETTE
Unidade examinadora
N70
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a design element consisting of three leaves in blue, fuchsia, and green, next to the wording "VALPHARMA" in black, with the first "A" featuring a blue leaf, the second "A" featuring a fuchsia leaf, and the terminal "A" featuring a green leaf, the wording "VALPHARMA" being above "GROUP" in black.
Titulares e representantes
Titulares
EURO HOLDING S.P.A.
Representantes
James L. Scott Warner Norcross + Judd LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for skin care; Pharmaceutical preparations for use in urology and dermatology; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disordersdiabetes; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Medicinal preparations for the mouth to be applied in the form of capsules and tablets; Veterinary preparations for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinaryoncologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinaldermatologicalimmune system related diseases and disorders; Veterinary preparations for the prevention and treatment of bacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disorders; Prescription synthetic narcotics and psychotropics; sanitary preparations for medical purposes; Bacteriological preparations for medical purposes; bacteriological preparations for veterinary purposes; dietetic food and substances in the nature of herbal teasdrinksbars for medical use; dietetic foods in the nature of a paste adapted for medical or veterinary use; food for babies; herbal preparations for medical purposes; herbal preparations for veterinary purposes; dietary supplements for humans and animals; nutraceuticals for therapeutic purposes in the nature of nutritional supplements; Nutraceuticals for use as a dietary supplement for animals; Nutraceuticals for use as a dietary supplement; Nutraceutical preparations for the treatment of ocular disorders or diseasesbacteria-based diseases or disorderssleep disordersautoimmune diseases or disordersallergiesrespiratory diseasekidney diseases or disordersdiabetes; Nutraceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Probiotic supplements; dietary and nutritional supplements; medicated food supplements; medical plasters; materials for dressings in the nature of gauze for dressingwadding for dressings
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
17/03/2022
FIMP
FINAL DISPOSITION PROCESSED
16/03/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
05/01/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
05/10/2021
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
20/07/2021
PUBO
PUBLISHED FOR OPPOSITION
20/07/2021
GPNX
NOTIFICATION PROCESSED BY IB
18/07/2021
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
30/06/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
30/06/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
30/06/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
14/06/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/06/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/06/2021
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
10/06/2021
NREP
NEW REPRESENTATIVE AT IB RECEIVED
09/04/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
05/01/2021
GNFR
FINAL REFUSAL E-MAILED
05/01/2021
CNFR
FINAL REFUSAL WRITTEN
05/01/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
30/12/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
29/12/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
29/12/2020
RFNT
REFUSAL PROCESSED BY IB
18/07/2020
NREP
NEW REPRESENTATIVE AT IB RECEIVED
10/07/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
29/06/2020
RFRR
REFUSAL PROCESSED BY MPU
29/06/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/05/2020
CNRT
NON-FINAL ACTION WRITTEN
27/05/2020
DOCK
ASSIGNED TO EXAMINER
20/05/2020
MAFR
APPLICATION FILING RECEIPT MAILED
05/05/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/05/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
30/04/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace VALPHARMA GROUP ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.